Business Wire

Pavilion Data Raises $25 Million in Series C Funding Round

13.8.2019 15:00:00 EEST | Business Wire | Press release

Share

Pavilion Data Systems, the industry leader in NVMe-over-Fabrics (NVMe-oF) storage technologies, announced today its Series C funding of $25 million, bringing the total funding to $58 million. New investors are Taiwania Capital and RPS Ventures.

All existing investors: Kleiner Perkins Caufield & Byers, Korea Investment Partners, DAG Ventures, Artiman Ventures, SK Telecom, and Tyche Partners participated in this round. The new investment will accelerate the delivery of the company's NVMe-oF products, expanding to new markets, and growing the team to support customer demand.

"The adoption of NVMe-oF is increasing, and Pavilion provides differentiated technology in this market. Repeat sales and strong customer demand prove that its NVMe-oF platform can bring competitive advantages to large organizations, especially those that rely on analytics and machine learning," said Huang Lee, managing partner at Taiwania. "We are pleased to lead this round and look forward to bringing Pavilion to new markets such as Asia where the cloud-scale deployments require an NVMe-oF solution without the complexities and limitations of traditional storage."

"Here at RPS Ventures, we appreciate the opportunity to join forces with Pavilion and the other investors to help the company expand to new verticals and other parts of the world," said Kabir Misra. managing partner at RPS. "When we decided to invest, we looked at the large, diverse customer base, but also the strong intellectual property. We were equally impressed by its OPENCHOICE business model and how it is changing the way storage is sold today."

"We are pleased with the Series C oversubscribed round of funding and our ongoing customer progress," said Gurpreet Singh, CEO of Pavilion Data. "In 2019, we have delivered a large number of systems to leading organizations worldwide. Many of these customers are now purchasing additional arrays as they continue to scale out. The platform is used in Artificial Intelligence, Machine Learning and Deep Learning workloads spanning IBM Spectrum Scale, MySQL, and NoSQL databases, as well as Pivotal™ Greenplum. We are also providing unification of modern cloud and legacy enterprise applications, including the Pivotal Cloud Foundry, Kubernetes with persistent K8s, and VMware. We solve their challenges with the immediate benefits of an NVMe-oF system and the procurement flexibility they need through our OPENCHOICE business model."

Pavilion was just awarded Best of Show – Most Innovative Startup at the Flash Memory Summit 2019. Earlier this year, the company was named an IDC NVMe over TCP Innovator, a CRN Hottest Storage Startups to Watch, became the first NVMe-oF solution for Spectrum Scale on IBM's Global Solutions Directory, became a Dell Extended Technologies Partner for direct and channel resale, and was awarded five patents for a total of 16 to date. The company is an active member of NVMexpress, SNIA, STAC Research, and TACC's STAR Program.

About Pavilion Data Systems

Pavilion Data Systems empowers organizations to make better decisions faster. Its ultra-fast, rack-scale NVMe-over-Fabric Storage Platform ingests, processes, stores and serves an order of magnitude more data for massively-parallel modern applications. Pavilion's OPENCHOICE Storage™ business model provides flexibility to reuse existing standard 2.5" NVMe SSDs or purchase the latest SSDs directly from drive makers, dramatically reducing procurement costs and future-proofing the platform investment. Pavilion Data's solutions enable Internet and SaaS companies, cloud service providers and enterprises to deliver business-critical applications at the speed of direct-attached storage, with the economics, reliability, manageability, and data management services of shared storage. To find out more, visit www.paviliondata.io or follow the company on Twitter at www.twitter.com/paviliondata.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pavilion Data Systems
Walter Hinton
720-394-7161
walter.hinton@paviliondata.io

Silicon Valley PR
Georgiana Comsa
650-800-7084
georgiana@siliconvalleypr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye